Friday Symposium Preceding the 61st American Society of Hematology Annual Meeting
Friday, December 6, 2019
Orlando Ballroom 3
The overall objective of this program is to fill the knowledge gap faced by practicing hematologists, oncologists, and hematopathologists due to rapid advancements in the laboratory diagnosis and elucidation of prognostic markers of plasma cell proliferative neoplasms.
In this course participants will learn, through exemplary cases, how our laboratory diagnostic testing algorithms and strategies provide guidance on optimal test utilization, while still maintaining the highest quality patient care in their own practices.
Hematologists, oncologists, hematopathologists, pathologists, and advanced practice providers (APPs) who provide care for patients with hematological disorders.
Upon completion of the conference, participants should be able to:
- Demonstrate utility of mass distributions of monoclonal proteins to detect and monitor plasma cell disorders.
- Discuss algorithms in peripheral blood/bone marrow evaluation for plasma cell neoplasms.
- Describe the role of FISH testing in risk stratification/prognosis in multiple myeloma.
- Identify why mate pair sequencing detects rearrangements that are missed by FISH approaches.
- Describe an approach to diagnostic work-up of lymphoplasmacytic lymphoma.
- Discuss role of laser capture microdissection/tandem mass spectrometry in the amyloidosis diagnostic algorithm.
As a provider accredited by ACCME, Mayo Clinic College of Medicine and Science (Mayo Clinic School of Continuous Professional Development) must ensure balance, independence, objectivity, and scientific rigor in its educational activities. Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.